Search

The objective of the study is to determine the usefulness of C-reactive protein (CRP) as a predictor of postoperative evolution after total joint arthroplasty (TJA). One hundred and three consecutive patients underwent TJA were included. CRP was determined at baseline, +2, +5 and +15 days. We defined three groups: normal (NP), early (EC) and late complications (LC). Postoperative complications were developed in 19 patients. On +5 day, the CRP in NP was significantly lower than in the EC group. A CRP< 6 mg/dl on day +5 had 60% sensitivity and 92% specificity to predict an uncomplicated postoperative course. A CRP<6 on +5 day is a useful marker to predict an uncomplicated postoperative course and, with the clinical evolution, could help us to suggest that these patients could be discharged sooner. [ABSTRACT FROM AUTHOR]

Background: We described the real‐life epidemiology and causes of infections on the different therapy phases in patients undergoing chimeric antigen receptor (CAR) T‐cells directed towards CD19+ or BCMA+ cells. Methods: All consecutive patients receiving CAR T‐cell therapy at our institution were prospectively followed‐up. We performed various comparative analyses of all patients and subgroups with and without infections. Results: Ninety‐one adults mainly received CAR T‐cell therapy for acute leukaemia (53%) and lymphoma (33%). We documented a total of 77 infections in 47 (52%) patients, 37 (48%) during the initial neutropenic phase and 40 (52%) during the non‐neutropenic phase. Infections during the neutropenic phase were mainly due to bacterial (29, 78%): catheter infections (11 [38%] cases), endogenous source (5 [17%]), and Clostridioides difficile (5 [17%]). Patients receiving corticosteroids after CAR T‐cell therapy had a higher risk of endogenous infection (100% vs. 16%; p =.006). During the non‐neutropenic phase, bacterial infections remained very frequent (24, 60%), mainly with catheter source (8, 33%). Respiratory tract infections were common (17, 43%). Conclusions: Infections after CAR T‐cell therapy were frequent. During the neutropenic phase, it is essential to prevent nosocomial infections and balance the use of antibiotics to lower endogenous bacteraemia and Clostridial infection rates. [ABSTRACT FROM AUTHOR]